Parabilis Medicines, Inc., formerly known as Cyclerion Therapeutics, Inc., is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of small-molecule therapeutics for people living with serious and orphan diseases. Parabilis leverages its deep expertise in the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) signaling pathway, specifically focusing on soluble guanylate cyclase (sGC) stimulators. These stimulators are designed to enhance the body's natural signaling to address various disease states. The company's lead therapeutic candidate, zagociguat, is a CNS-penetrant sGC stimulator currently being evaluated for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as other mitochondrial diseases where impaired signaling plays a critical role. Following its rebranding from Cyclerion in 2024, Parabilis continues to advance its clinical pipeline while seeking strategic opportunities to expand its portfolio. The company aims to address significant unmet medical needs by targeting the underlying biology of rare and debilitating conditions through precision pharmacology.